BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

625 related articles for article (PubMed ID: 15519007)

  • 1. Contrast-induced nephropathy in patients undergoing primary angioplasty for acute myocardial infarction.
    Marenzi G; Lauri G; Assanelli E; Campodonico J; De Metrio M; Marana I; Grazi M; Veglia F; Bartorelli AL
    J Am Coll Cardiol; 2004 Nov; 44(9):1780-5. PubMed ID: 15519007
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prediction of contrast-induced nephropathy in diabetic patients undergoing elective cardiac catheterization or PCI: role of volume-to-creatinine clearance ratio and iodine dose-to-creatinine clearance ratio.
    Worasuwannarak S; Pornratanarangsi S
    J Med Assoc Thai; 2010 Jan; 93 Suppl 1():S29-34. PubMed ID: 20364554
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk stratification according to the type of impaired renal function in patients with acute myocardial infarction treated with percutaneous coronary intervention.
    Kowalczyk J; Lenarczyk R; Kowalski O; Swiatkowski A; Stabryła-Deska J; Kurek T; Honisz G; Kukulski T; Gasior M; Kalarus Z
    Kardiol Pol; 2007 Jun; 65(6):635-43; discussion 644. PubMed ID: 17629825
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Contrast-induced nephropathy in patients undergoing emergency percutaneous coronary intervention for acute coronary syndrome.
    Senoo T; Motohiro M; Kamihata H; Yamamoto S; Isono T; Manabe K; Sakuma T; Yoshida S; Sutani Y; Iwasaka T
    Am J Cardiol; 2010 Mar; 105(5):624-8. PubMed ID: 20185007
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of gender on the incidence and outcome of contrast-induced nephropathy after percutaneous coronary intervention.
    Iakovou I; Dangas G; Mehran R; Lansky AJ; Ashby DT; Fahy M; Mintz GS; Kent KM; Pichard AD; Satler LF; Stone GW; Leon MB
    J Invasive Cardiol; 2003 Jan; 15(1):18-22. PubMed ID: 12499523
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of high-dose N-acetylcysteine versus placebo on contrast-induced nephropathy and myocardial reperfusion injury in unselected patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. The LIPSIA-N-ACC (Prospective, Single-Blind, Placebo-Controlled, Randomized Leipzig Immediate PercutaneouS Coronary Intervention Acute Myocardial Infarction N-ACC) Trial.
    Thiele H; Hildebrand L; Schirdewahn C; Eitel I; Adams V; Fuernau G; Erbs S; Linke A; Diederich KW; Nowak M; Desch S; Gutberlet M; Schuler G
    J Am Coll Cardiol; 2010 May; 55(20):2201-9. PubMed ID: 20466200
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence, predictors, and outcomes of post-percutaneous coronary intervention nephropathy in patients with diabetes mellitus and normal baseline serum creatinine levels.
    Roy P; Raya V; Okabe T; Pinto Slottow TL; Steinberg DH; Smith K; Xue Z; Satler LF; Kent KM; Suddath WO; Pichard AD; Lindsay J; Waksman R
    Am J Cardiol; 2008 Jun; 101(11):1544-9. PubMed ID: 18489931
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Procedural success versus clinical risk status in determining discharge of patients after primary angioplasty for acute myocardial infarction.
    Heggunje PS; Harjai KJ; Stone GW; Mehta RH; Marsalese DL; Boura JA; O'Neill WW; Grines CL
    J Am Coll Cardiol; 2004 Oct; 44(7):1400-7. PubMed ID: 15464319
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Frequency and predictors of contrast-induced nephropathy after angioplasty for chronic total occlusions.
    Aguiar-Souto P; Ferrante G; Del Furia F; Barlis P; Khurana R; Di Mario C
    Int J Cardiol; 2010 Feb; 139(1):68-74. PubMed ID: 19056138
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mortality after emergent percutaneous coronary intervention in cardiogenic shock secondary to acute myocardial infarction and usefulness of a mortality prediction model.
    Klein LW; Shaw RE; Krone RJ; Brindis RG; Anderson HV; Block PC; McKay CR; Hewitt K; Weintraub WS;
    Am J Cardiol; 2005 Jul; 96(1):35-41. PubMed ID: 15979429
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In-hospital and one-year outcomes of patients with high-risk acute myocardial infarction treated with thrombolysis or primary coronary angioplasty.
    Steffenino G; Santoro GM; Maras P; Mauri F; Ardissino D; Violini R; Chiarella F; Lucci D; Marini M; Baldasseroni S; Maggioni AP;
    Ital Heart J; 2004 Feb; 5(2):136-45. PubMed ID: 15086144
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of acute renal failure following percutaneous coronary intervention on long-term mortality.
    Roghi A; Savonitto S; Cavallini C; Arraiz G; Angoli L; Castriota F; Bernardi G; Sansa M; De Servi S; Pitscheider W; Danzi GB; Reimers B; Klugmann S; Zaninotto M; Ardissino D;
    J Cardiovasc Med (Hagerstown); 2008 Apr; 9(4):375-81. PubMed ID: 18334892
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Female sex and risk of contrast nephropathy after percutaneous coronary intervention.
    Mueller C; Buerkle G; Perruchoud AP; Buettner HJ
    Can J Cardiol; 2004 Apr; 20(5):505-9. PubMed ID: 15100752
    [TBL] [Abstract][Full Text] [Related]  

  • 14. B-type natriuretic peptide for prevention of contrast-induced nephropathy in patients with heart failure undergoing primary percutaneous coronary intervention.
    Zhang J; Fu X; Jia X; Fan X; Gu X; Li S; Wu W; Fan W; Su J; Hao G; Jiang Y; Xue L
    Acta Radiol; 2010 Jul; 51(6):641-8. PubMed ID: 20438292
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypertension is an independent risk factor for contrast nephropathy after percutaneous coronary intervention.
    Conen D; Buerkle G; Perruchoud AP; Buettner HJ; Mueller C
    Int J Cardiol; 2006 Jun; 110(2):237-41. PubMed ID: 16298441
    [TBL] [Abstract][Full Text] [Related]  

  • 16. N-acetylcysteine and contrast-induced nephropathy in primary angioplasty.
    Marenzi G; Assanelli E; Marana I; Lauri G; Campodonico J; Grazi M; De Metrio M; Galli S; Fabbiocchi F; Montorsi P; Veglia F; Bartorelli AL
    N Engl J Med; 2006 Jun; 354(26):2773-82. PubMed ID: 16807414
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Statins for prevention of contrast-induced nephropathy in patients undergoing non-emergent percutaneous coronary intervention.
    Kandula P; Shah R; Singh N; Markwell SJ; Bhensdadia N; Navaneethan SD
    Nephrology (Carlton); 2010 Mar; 15(2):165-70. PubMed ID: 20470274
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparison of contemporary definitions of contrast nephropathy in patients undergoing percutaneous coronary intervention and a proposal for a novel nephropathy grading system.
    Harjai KJ; Raizada A; Shenoy C; Sattur S; Orshaw P; Yaeger K; Boura J; Aboufares A; Sporn D; Stapleton D
    Am J Cardiol; 2008 Mar; 101(6):812-9. PubMed ID: 18328846
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Different types of renal dysfunction in patients with acute myocardial infarction treated with percutaneous coronary intervention.
    Kowalczyk J; Lenarczyk R; Kowalski O; Sredniawa B; Musialik-Lydka A; Gasior M; Polonski L; Zembala M; Gumprecht J; Kalarus Z
    J Interv Cardiol; 2007 Apr; 20(2):143-52. PubMed ID: 17391223
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Contrast medium dose-to-GFR ratio: a measure of systemic exposure to predict contrast-induced nephropathy after percutaneous coronary intervention.
    Nyman U; Björk J; Aspelin P; Marenzi G
    Acta Radiol; 2008 Jul; 49(6):658-67. PubMed ID: 18568558
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.